FIELD: biotechnology.
SUBSTANCE: invention discloses a modified antibody or its fragment binding to angiopoietin-2, a nucleic acid coding the said antibody or its fragment, an expression vector and a cell containing the said nucleic acid, a method of producing the antibody or its fragment.
EFFECT: improved modified antibody according to the invention, in which amino acids located in the frame region have been replaced, has high solubility, which enables to concentrate it to a high level.
9 cl, 15 dwg, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST ANG2 AND ITS USE | 2020 |
|
RU2788088C1 |
| ANTIBODIES AGAINST PROGRAMMED CELL DEATH LIGAND 1 AND THEIR USE | 2020 |
|
RU2786235C1 |
| ANTI-VSIG4 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF | 2020 |
|
RU2826236C1 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| ANTIBODY AGAINST TIE-2 AND ITS USE | 2020 |
|
RU2795455C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
